Table 1 Characteristics of patients and tumors at baseline (n = 99)
From: Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial
Age | |
Median (range), years | 57.0 (48.0–66.0) |
Sex, n (%) | |
Female | 99 (100.0) |
ECOG PS, n (%) | |
0 | 56 (56.6) |
1 | 40 (40.4) |
N/A | 3 (3.0) |
Menopausal status, n (%) | |
Premenopausal | 23 (23.2) |
Postmenopausal | 75 (75.8) |
N/A | 1 (1.0) |
Stage at initial tumor diagnosis, n (%) | |
I | 13 (13.1) |
II | 19 (19.2) |
III | 11 (11.1) |
IV | 30 (30.3) |
N/A | 26 (26.3) |
HR status at initial tumor diagnosis, n (%) | |
ER+PR+ | 76 (76.8) |
ER+PR− | 18 (18.2) |
ER−PR− | 1 (1.0) |
N/A | 3 (3.0) |
HER2 expression at initial tumor diagnosis, n (%) | |
IHC 0 | 56 (56.6) |
IHC 1+ | 22 (22.2) |
IHC 2+, ISH nonamplified | 11 (11.1) |
IHC 2+, ISH amplified | 1 (1.0) |
Unknown | 9 (9.1) |
HER2 expression on tumor biopsy at baseline, n (%) | |
IHC 0a | 39 (39.4) |
IHC 1+ | 22 (22.2) |
IHC 2+, ISH− | 7 (7.1) |
IHC 3+ | 1 (1.0) |
Unknown | 30 (30.3)b |
HER3 expression | |
Membrane H-score, median (range) | 180 (0–290) |
Overall membrane positivity at 10×, n (%) | |
<25% | 16 (16.2) |
25–74% | 7 (7.1) |
≥75% | 49 (49.4) |
Unknown | 27 (27.3) |
Metastatic sites at study entry, n (%) | |
Liver | 60 (60.6) |
Lung | 8 (8.1) |
Nodes | 9 (9.1) |
Brain | 0 (0) |
Median number of systemic therapies for ABC, n (range) | 2 (1–4) |
Previous treatment with CDK4/ 6inh, n (%) | 98 (99.0)c |
Median duration of CDK4/6inh, months (range) | 13.7 (2.9–42.0)d |
Previous PI3K–AKT–mTOR inh for ABC, n (%) | 35 (35.4) |
Previous chemotherapy for ABC, n (%) | 99 (100.0) |
Type of chemotherapy for ABC, n (%) | |
Capecitabine | 53 (53.6) |
Taxanes | 23 (23.2) |
Others | 23 (23.2) |
